Tag Archives: SRPT

Friday’s Midday Stock Update: Agios Pharma (AGIO), Sangamo Biosciences (SGMO), Sarepta Therapeutics (SRPT), Glu Mobile (GLUU), Karyopharm Therapeutics (KPTI)

So far Friday, November 8, NASDAQ is up 1.09% and the S&P is up 0.49%. Here are this morning’s most active stocks: Agios Pharma (AGIO – Research Report), Sangamo Biosciences (SGMO – Research Report), Sarepta Therapeutics (SRPT – Research Report),

Thursday’s Midday Stock Update: Rite Aid Corp (RAD), uniQure NV (QURE), Heron Therapeutics (HRTX), Karyopharm Therapeutics (KPTI), Sarepta Therapeutics (SRPT)

So far Thursday, October 3, NASDAQ is up 1.61% and the S&P is up 1.52%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Rite Aid Corp (RAD – Research Report), uniQure NV (QURE

The EVP, CFO & CBO of Sarepta Therapeutics is Exercising Options

Yesterday it was reported that the EVP, CFO & CBO of Sarepta Therapeutics (SRPT – Research Report), Sandesh Mahatme, exercised options to buy 9,754 SRPT shares at $24.73 a share, for a total transaction value of $241.2K. Following Sandesh Mahatme’s

A Director at Sarepta Therapeutics (NASDAQ: SRPT) is Buying Shares

Today, a Director at Sarepta Therapeutics (SRPT – Research Report), Richard Barry, bought shares of SRPT for $453.3K. In addition to Richard Barry, one other SRPT executive reported Buy trades in the last month. See today’s analyst top recommended stocks

William Blair Maintains Their Buy Rating on Sarepta Therapeutics (SRPT)

In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report). The company’s shares opened today at $126.11. According to TipRanks.com, Lugo is a 4-star analyst with an average return

Analysts Are Bullish on Top Healthcare Stocks: Sarepta Therapeutics (SRPT), RegenXBio (RGNX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), RegenXBio (RGNX – Research Report) and Prothena Corp (PRTA – Research Report) with bullish sentiments. Sarepta